Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00659178 · ClinicalTrials.gov registry record · Phase 1
Combination Study Of SB-485232 (Interleukin 18) And Doxil For Advanced Stage Epithelial Ovarian Cancer
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT00659178 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 15 participants.
The verdict
NCT00659178, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this study is to identify a dose of SB-485232 which is safe, tolerable and biologically active when used in combination with pegylated liposomal doxorubicin (Doxil) in patients with epithelial ovarian cancer. This study will use a standard treatment regimen of pegylated liposomal doxorubicin (Doxil) in combination with rising doses of SB-485232. The dose selected from this study will be used in a future studies to evaluate the efficacy of this combination.
Interventions
- DRUG SB-485232 (interleukin 18), pegylated liposomal doxorubicin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2008-06-18 |
| Est. Completion | 2011-02-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00659178
The ClinicalTrials.gov registry entry for NCT00659178 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SB-485232 (interleukin 18), pegylated liposomal doxorubicin is the first listed.
NCT00659178 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00659178 about?
NCT00659178 is a clinical study titled "Combination Study Of SB-485232 (Interleukin 18) And Doxil For Advanced Stage Epithelial Ovarian Cancer". The purpose of this study is to identify a dose of SB-485232 which is safe, tolerable and biologically active when used in combination with pegylated liposomal doxorubicin (Doxil) in patients with epithelial ovarian cancer. This study will use a standard treatment regimen of pegylated liposomal doxo...
What is the current status of trial NCT00659178?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2008-06-18. Estimated completion is 2011-02-18.
What interventions are being tested in trial NCT00659178?
The interventions under investigation include: SB-485232 (interleukin 18), pegylated liposomal doxorubicin (DRUG).
Who is sponsoring clinical trial NCT00659178?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.